Angiotensin converting enzyme (ACE) is a drug target and an effective bradykinin (BK)-inactivating ectopeptidase. We exploited a recently described 
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Introduction
Bradykinin (BK) is the prototype kinin released from kininogens by kininogenases. It exerts its cardiovascular actions largely via stimulation of B 2 receptors located in endothelial cells [19] . BK is rapidly disposed of in vivo and ACE seems to be the most effective kininase, with high affinity and substrate turnover [4, 7, 8] . ACE inhibitors assume an important place in cardiovascular and renal disease management; they prevent the activation reaction of angiotensin I, but a fraction of their beneficial effects may derive from the potentiation of endogenous BK in humans [12, 26, 33] .
ACE expression is constitutive in endothelial cells and some renal epithelial cells and inducible in some other lineages [10] . Endothelial ACE may be regulated by the rate of its synthesis and the cleavage and/or shedding of surface ACE [5, 17, 27] . In human umbilical vein endothelial cells (HUVECs), the transcription of the ACE gene mRNA and ACE activity are known to be stimulated by protein kinase (PK) A and PKC [30, 35, 36] and slightly via NO-controlled PKG [28] , and repressed by the inflammatory cytokines IL-- [25, 29] . It is not known whether these in vitro findings are predictive of enzyme variations of physiopathological importance, although large and opposite variations of ACE activities were recently reported in the heart membranes prepared from rats with type I and II diabetes (decreased and increased activities, respectively [1] ).
The present study had 2 major objectives: firstly, we studied the affinities for ACE of a set of physiological or synthetic peptide substrates using the recently described [ 3 H]enalaprilat binding assay [23] . Secondly, the same assay was exploited to quantify the full dynamic range of ACE 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   5 
Materials and Methods

Drugs, peptides and reagents
BK, human recombinant insulin, phorbol 12-myristate 13-acetate (PMA), TPCA-1, GF109203x,
angiotensins, PD98059 and Ac-SDKP were purchased from Sigma-Aldrich (St. Louis, MO, USA 
Cells and radioligand binding assays
The institutional research ethics board approved the anonymous use of human umbilical cord segments obtained after elective caesarean section deliveries. Primary cultures of endothelial cells from the human umbilical vein (HUVECs) were obtained and propagated as described [14] .
Briefly, HUVECs were isolated by collagenase digestion of umbilical veins from undamaged sections of fresh cords. T at 37°C. After perfusion, the detached cells were collected, the vein was washed with medium 199, and the wash-off was pooled with the perfusate. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   7 min of incubation at 37°C, each well was washed three times with 2 ml of ice-cold phosphatebuffered saline (PBS), pH 7.4. One milliliter of 0.1 M NaOH was finally added to dissolve the cells. Radioactivity in the resulting suspension was determined by scintillation counting (5 min per vial).
Microscopy
To evaluate the localization of ACE in freshly isolated human umbilical blood vessels, immunostaining was applied to paraffin section of the vein and artery using the anti-ACE The translocation of NFmaintained in their regular culture medium 60-90 min after drug treatments using immunofluorescence as described [22] . 
Immunoblots
Data analysis
All numerical data were expressed as means ± standard error of the mean (s.e.m.) for n values. 
Results
Localization of ACE in section of the fresh human umbilical vein
Consistent with the high B max of the ACE ligand [ 3 H]enalaprilat in cultured HUVECs, but very low binding in cultured vascular smooth muscle [23] , the anti-ACE antibody labeled the endothelial inner surface of the fresh human umbilical vein ( Fig. 1 ) and artery (data not shown), also positive for von Willebrand factor. However, the underlying smooth muscle layers, positive -actin, were negative for ACE (immunohistochemistry). The same anti-ACE antibodies were exploited in immunoblots of HUVEC lysates (see below).
Binding of BK-related and other potential substrates to ACE
The binding of a saturating concentration (2 nM) of [ 3 H]enalaprilat to intact HUVECs has been previously shown to be displaced by several ACE inhibitor drugs [23] . We extended these investigations to potential ACE substrates related to BK ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 not angiotensin II, and Ac-0] (Fig.   2C ).
Modulation of ACE expression as assessed by [ 3 H]enalaprilat binding
HUVECs express ACE in a regulated manner (see Introduction). An original approach, (Fig. 3A) . However, immunoblotting ACE allowed an experiment that was not possible using the binding assay: it was shown that 24-h treatment with a high concentration (1 µM) of the non radioactive ACE inhibitor enalaprilat had no strong effects on ACE expression (Fig. 3B) . One-h treatments with any of the 3 stimuli had no significant effect on ACE abundance.
Further characterization of signaling pathways that affect ACE expression in HUVECs
The PKC inhibitor GF109203x (5 µM) prevented the effect of PMA on ACE expression, but not that of TNF- (Fig. 3A) . Further, the alternate inflammatory cytokine IL- The stimulant effect of PMA on ACE expression was analyzed using staurosporin analogs that show good selectivity within the PKC family and some isoform-selective specificity as a function of the concentration [18] (Fig. 6) . The general PKC inhibitor GF109203x (0.5-5 µM) and that of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13 calcium sensitive isoforms Gö6976 (3 µM) both reduced the effect of PMA on ACE density without affecting the baseline expression of the enzyme in the absence of PMA. LY 379196 is a close analog of GF 109203x that has been developed [15] . It had no effect of PMA-induced ACE regulation in a concentration range that is believed to be isoformspecific.
MAP kinases are often signaling intermediates for extracellular stimuli that influence gene expression. MAP kinase and other signaling were probed in lysates of HUVECs submitted to treatments that affect ACE expression and to BK stimulation ( the heterogenous molecular weight aspect suggestive of the multiple phosphorylation events that are associated with its nuclear translocation [13] . All the observed signaling responses to stimuli faded in cells treated for 24 h (data not shown).
Using pharmacological inhibitors of MAP kinase pathways, we verified the effects of the responsive pathways on ACE expression. Cotreatment with the inhibitor of of p38, SB203,580, partially and significantly reversed the inhibitory effect of TNFendothelial ACE (Fig. 7B) ; however, the drug treatment also slightly but significantly increased the ACE expression in control cells. PD98059, the inhibitor of MEK1, the MAP kinase upstream of ERK1/2, importantly and significantly abated the stimulatory effect of PMA on the density of [1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 TNF--treated HUVECs (Fig. 7B) . We controlled that the acute effect of PMA (30 min) on ERK1/2 phosphorylation was inhibited by cotreatment with PD98059, but also by the PKC inhibitor GF209103x (Fig. 8A) , thus positioning the PKC signaling intermediate between the phorbol ester and MEK1. Acute c-Fos induction by PMA (60 min), an event better correlated with ACE upregulation than ERK1/2 phosphorylation (Fig. 7A) , was nevertheless suppressed by the MEK1 inhibitor PD98059 and the PKC inhibitor (Fig. 8B) . As for the effect of p38 signaling on ACE expression, it was shown that TNF--induced p38 phosphorylation was greatly reduced by the IKK2 inhibitor TPCA-1, but much less by the p38 inhibitor SB203,580 (Fig. 8C ),
positioning NF-mediation upstream of p38 signaling. The slight effect of SB203,580 on phospho-p38 may not be specific, as the drug should rather inhibit the kinase activity of p38 on downstream substrates.
Specificity of stimuli that affect ACE expression
Epidermal growth factor (EGF, 100 nM, 24 h) or high glucose (22.2 mM in the culture medium, 72-h treatment shown, but also applies to 24-h treatment) failed to influence ACE expression (Fig. 9A) . EGF exerted an acute effect on cells, EGR receptor phosphorylation in 15 min (Fig.   9A , bottom), while high glucose is reportedly a stimulus for the upregulation of endothelin converting enzyme-1 in HUVECs [16] . Human recombinant insulin (1-5 µM, 24 h) did not appreciably change the density of ACE molecules at the surface of endothelial cells, despite the fact that HUVECs were acutely responsive to insulin (Akt phosphorylation in 30 min, Fig. 9B ). 
Discussion
Cell type specificity of ACE expression
The expression of the ACE gene product is regulated both in a cell type-specific manner and by physiological factors. Thus, in vascular tissue, ACE is largely restricted to endothelial cells, the smooth muscle cells being negative (immunohistochemistry of umbilical vessel sections, Fig. 1 ; 
Peptide binding to ACE
When BK-related peptides are used as competitors of the radiolabelled ACE inhibitor in the binding assay, the known preference for intact kinin C-terminus sequences emerges, with BK and Lys-BK being the substrates of highest affinity ( fig. 2A) . The des-Arg 9 -kinins that are B 1 receptor agonists exhibit only very little capacity to compete for [ 3 H]enalaprilat in the applied assay, although ACE is a significant but slow and nonexclusive degradation pathway for these peptides in various physiological settings [7, 11] . The binding site differs from the BK B 2 receptor by the low or null affinity of ligands that have been designed to resist to inactivation (the agonist B-9972 and the nonpeptide antagonist LF 16-0687, Fig. 2B ) and by the measurable affinity of physiological substrates unrelated to kinins, angiotensin I and Ac-SDKP ( fig. 2C ). However, these peptides exhibit an affinity much lower than that of BK, in line with the fact that ACE is a particularly effective kininase (see Introduction).
Pharmacological modulators of ACE expression in HUVECs: dynamic range, interactions, specificity and further characterization of signaling
The present study addressed the regulation of endothelial ACE expression using original pharmacological approaches, the [ 3 H]enalaprilat binding assay in intact cells, further corroborated with ACE immunoblots. Relative to the levels recorded in HUVECs maintained in the full culture medium, previously described treatments increased (PMA) or decreased (inflammatory cytokines) the density of ACE [29, 30, 35] . Further, both types of stimuli interacted, as TNF---induced ACE expression (Fig. 4A) . The previously identified pathways have some selectivity, as insulin, high glucose or EGF had no influence on ACE density under similar conditions (Fig. 9 ). Although acute ERK1/2 phosphorylation was observed in enalaprilat-stimulated HUVECs (Fig. 7A) , possibly confirming direct ACE inhibitorinduced signaling via ACE [10, 17] , this hypothetical pathway does not importantly feed back on ACE expression, based on ACE immunoblots (Fig. 3B ). Functional B 2 receptors are presumably present in HUVECs in this and previous studies [21] , notably because BK acutely activates ERK1/2 phosphorylation (Fig. 7A) . Thus, it remains to be seen whether autocrine kinins can account for enalaprilat-induced signaling in these cells. Interestingly for the possible effect of diabetic states on ACE expression [1] , high glucose failed to influence ACE expression in HUVECs (Fig. 9) ; the 24-72 h-high glucose treatment applied in the present study is a major modulator of endothelin converting enzyme-1 expression in these cells [16] .
The inhibitory effect of TNF--2 NFsignaling pathway, as shown by the significant reversal of the inhibition by the IKK-2 inhibitor TPCA-1 (Fig. 4B) . We have also observed that TNF--induced p38-mediated signaling is downstream of that of NF-, being abolished by TPCA-1 (Fig. 8 , schematic representation of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 17 signaling, Fig. 10 ). In fact, the amount of ACE in control cultured HUVECs may be the result of equilibrium between p38-and inflammatory cytokine-mediated downregulation and mitogen-and ERK1/2-mediated upregulation, as based on the effect of MAP kinase inhibitors on control cells.
Autocrine IL-1, some of which remains associated to cells, is measurable in control HUVECs and increases in response to mitogens used in the culture medium [20] and may influence this hypothetical equilibrium. However, the addition of exogenous inflammatory cytokines shows the full extent of inflammatory ACE repression. This may be relevant for inflammatory/infectious states, in which the vascular actions of kinins as mediators of inflammation may be potentiated due to loss of this major kininase. In addition, insulin-dependent diabetes models in rodents are associated with high TNFerved that, in the heart, the activity of ACE decreases in the weeks that follow induction of this pathology with streptozotocin [1] . This alteration, which is a likely result of inflammatory cytokine action in vivo, was fully reversed by insulin treatment. Insulin itself had no effect on ACE expression in HUVECs (Fig. 9B ) despite the fact that HUVECs acutely responded to it (Akt phosphorylation).
The previously described PKC-mediated endothelial upregulation of ACE [30, 35] has been reproduced using the [ increase of c-Fos expression (Fig. 7A) , itself controlled at least in part by upstream MEK1-ERK1/2 MAP kinases and the GF109203x-sensitive PKC (Fig. 8A, 8B, 10 ). It had been previously noted that PMA-induced ACE expression is dependent on the transcription factor activating protein-1 (AP-1) [9] , of which c-Fos is a constituent. A physiopathological example of ACE upregulation by such conditions may be the prediabetic state in Zucker rats where diacylglycerol, the endogenous PKC stimulant, is increased in vascular tissue, as well as the expression of several PKC isoforms [24] . This may explain the high ACE activity and low BK half-life in membranes isolated from young, prediabetic Zucker rats relative to Sprague-Dawley rats [1] , and may deprive diabetic individuals from the postulated protective effects of low kinin levels in tissues.
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HUVECs. The drugs were given alone or with one of the modulators TNF-(1 µM) for 24 h. Groups of values corresponding to each or no modulator were heterogeneous inhibitors: * P<0.05; ** P<0.01. 
